EE256 Comparative Cost-Utility Analysis of Galcanezumab and Fremanezumab for Migraine Prevention in Individuals with Chronic Migraine Who Have Tried 2 to 4 Prior Preventive Treatments
Abstract
Authors
S. Bhardwaj M. Zimmermann L. Garrison